​

Amicus Therapeutics (FOLD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

FOLD Stock Forecast

Amicus Therapeutics (FOLD) stock forecast, based on 22 Wall Street analysts, predicts a 12-month average price target of $14.00, with a high of $14.00 and a low of $14.00. This represents a 58.01% increase from the last price of $8.86.

$8 $9 $10 $11 $12 $13 $14 $15 High: $14 Avg: $14 Low: $14 Last Closed Price: $8.86

FOLD Stock Rating

Amicus Therapeutics stock's rating consensus is Buy, based on 22 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 19 Buy (86.36%), 2 Hold (9.09%), 1 Sell (4.55%), and 0 Strong Sell (0.00%).

Buy
Total 22 0 1 2 19 Strong Sell Sell Hold Buy Strong Buy

FOLD Price Target Upside V Benchmarks

TypeNameUpside
StockAmicus Therapeutics58.01%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-11
Avg Price Target-$14.00$14.00
Last Closing Price$8.86$8.86$8.86
Upside/Downside-58.01%58.01%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25381--12
Sep, 25282--12
Aug, 25282--12
Jul, 25183--12
Jun, 25183--12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 18, 2025Needham$14.00$8.3168.47%58.01%
Oct 17, 2024Tazeen AhmadBank of America Securities$15.00$12.0324.69%69.30%
May 14, 2024Debjit ChattopadhyayGuggenheim$13.00$9.0443.81%46.73%
May 09, 2024Jeffrey HungMorgan Stanley$19.00$9.48100.42%114.45%
Dec 19, 2023Jeffrey HungMorgan Stanley$20.00$12.6657.98%125.73%
May 10, 2021Salveen RichterGoldman Sachs$14.00$9.3949.09%58.01%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 18, 2025NeedhamBuyupgrade
Jul 16, 2025Morgan StanleyUnderweightOverweightupgrade
May 02, 2025UBSBuyBuyhold
Oct 23, 2024Cowen & Co.BuyBuyhold
Oct 17, 2024Bank of America SecuritiesBuyBuyhold
Oct 11, 2024JefferiesBuyBuyhold
Sep 06, 2024JefferiesBuyinitialise
Jul 22, 2024Cowen & Co.BuyBuyhold
May 30, 2024Wells FargoOverweightinitialise
May 14, 2024UBSBuyBuyhold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.07$-0.92$-0.82$-0.51$-0.18----
Avg Forecast$-1.02$-0.78$-0.77$-0.45$-0.21$0.13$0.46$0.97$1.45
High Forecast$-0.98$-0.75$-0.75$-0.42$-0.12$0.18$0.76$1.06$1.48
Low Forecast$-1.07$-0.82$-0.81$-0.48$-0.27$0.09$0.33$0.86$1.41
Surprise %4.90%17.95%6.49%13.33%-14.29%----

Revenue Forecast

$250M $440M $630M $820M $1B $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$260.89M$305.51M$329.23M$399.36M$528.29M----
Avg Forecast$261.00M$307.12M$327.45M$398.70M$528.08M$637.75M$785.14M$983.63M$1.18B
High Forecast$270.11M$317.84M$339.05M$398.78M$536.44M$647.84M$789.26M$996.13M$1.20B
Low Forecast$252.63M$297.27M$319.04M$398.62M$518.07M$625.65M$781.02M$971.13M$1.16B
Surprise %-0.04%-0.52%0.55%0.16%0.04%----

Net Income Forecast

$-350M $-190M $-30M $130M $290M $450M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-276.85M$-250.46M$-236.57M$-151.58M$-56.11M----
Avg Forecast$-301.47M$-213.45M$-244.79M$-151.58M$-58.06M$39.08M$145.28M$284.60M$427.01M
High Forecast$-288.89M$-170.76M$-195.83M$-121.27M$-35.10M$52.44M$224.33M$312.87M$435.79M
Low Forecast$-315.14M$-256.14M$-293.75M$-181.90M$-81.01M$27.97M$97.40M$253.84M$416.48M
Surprise %-8.16%17.34%-3.36%--3.36%----

FOLD Forecast FAQ

Is Amicus Therapeutics stock a buy?

Amicus Therapeutics stock has a consensus rating of Buy, based on 22 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 19 Buy, 2 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Amicus Therapeutics is a favorable investment for most analysts.

What is Amicus Therapeutics's price target?

Amicus Therapeutics's price target, set by 22 Wall Street analysts, averages $14 over the next 12 months. The price target range spans from $14 at the low end to $14 at the high end, suggesting a potential 58.01% change from the previous closing price of $8.86.

How does Amicus Therapeutics stock forecast compare to its benchmarks?

Amicus Therapeutics's stock forecast shows a 58.01% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Amicus Therapeutics over the past three months?

  • October 2025: 25.00% Strong Buy, 66.67% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 16.67% Strong Buy, 66.67% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 16.67% Strong Buy, 66.67% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.

What is Amicus Therapeutics’s EPS forecast?

Amicus Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $0.13, marking a -172.22% decrease from the reported $-0.18 in 2024. Estimates for the following years are $0.46 in 2026, $0.97 in 2027, and $1.45 in 2028.

What is Amicus Therapeutics’s revenue forecast?

Amicus Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $637.75M, reflecting a 20.72% increase from the reported $528.3M in 2024. The forecast for 2026 is $785.14M, followed by $983.62M for 2027, and $1.18B for 2028.

What is Amicus Therapeutics’s net income forecast?

Amicus Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $39.08M, representing a -169.65% decrease from the reported $-56.106M in 2024. Projections indicate $145.28M in 2026, $284.6M in 2027, and $427.01M in 2028.